Core Viewpoint - The long-term study of Wegovy (semaglutide) demonstrates its effectiveness in weight management and cardiovascular benefits for overweight or obese patients with cardiovascular diseases, showing an average weight loss of approximately 10% over four years with sustained results for 65 weeks without rebound [2][6][13]. Study Design - The SELECT trial, the longest clinical trial to date, involved 17,604 participants from 41 countries, assessing the impact of Wegovy versus placebo over four years [5][9]. - The primary endpoint was the time to the first occurrence of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke [10]. Efficacy of Wegovy - Results indicated that 67.8% of participants in the Wegovy group lost 5% or more of their body weight, compared to 21.3% in the placebo group. The percentages for losing 10%, 15%, 20%, and 25% were 44.2%, 22.9%, 11%, and 4.9% respectively, versus 6.9%, 1.7%, 0.6%, and 0.1% in the placebo group [11]. - After 104 weeks, approximately 52.4% of Wegovy patients showed improvement in BMI, while only 15.7% in the placebo group did [11]. Weight Loss and Measurements - The average weight loss in the Wegovy group was 10.2%, with a waist circumference reduction of 7.7 cm, compared to a 1.5% weight loss and 1.3 cm reduction in the placebo group [13]. - The waist-to-height ratio decreased by 6.9% in the Wegovy group, while the placebo group saw a decrease of 1.0% [13]. Side Effects - 16.6% of patients in the Wegovy group discontinued due to adverse events, compared to 8.2% in the placebo group. Serious adverse events were reported by approximately 33.4% in the Wegovy group and 36.4% in the placebo group [14]. - The study found a lower association of serious adverse events with Wegovy, particularly those related to cardiovascular diseases or infections [14]. Future Research - The SELECT Life trial will follow participants from the SELECT trial to gather long-term data on the effects of Wegovy [16].

Core Viewpoint - The article emphasizes the significant association between weight fluctuation and cardiovascular disease prognosis, highlighting the need for effective clinical weight management strategies for patients with obesity and cardiovascular conditions [6][9][11]. Group 1: Obesity and Cardiovascular Disease - Cardiovascular disease is the leading global health killer, with obesity identified as a key risk factor [6]. - Approximately 40% of adults in the U.S. face obesity issues, and the UK's National Health Service spends around £6 billion annually on obesity-related healthcare [6]. - Among cardiovascular disease patients, the obesity detection rate is as high as 38%, leading to severe impacts on quality of life and significant socio-economic burdens [6]. Group 2: Research Findings - A recent study published in the journal "Heart" utilized data from the UK Biobank to analyze the relationship between weight changes and cardiovascular outcomes [9]. - The study involved 8,297 obese patients with cardiovascular disease, revealing that significant weight gain is associated with increased risks of cardiovascular and all-cause mortality [10][11]. - The average age of participants was 56.6 years, with a median follow-up period of 13.9 years, providing clinically significant findings [9]. Group 3: Weight Fluctuation Impact - Over half (52.7%) of the patients maintained stable weight during the study, while 14.2% experienced significant weight loss (≥10 kg) and 5.1% had notable weight gain (≥10 kg) [10]. - Weight gain was linked to a 3.05-fold increase in cardiovascular death risk and a 1.93-fold increase in all-cause mortality risk, while weight loss did not show similar risk changes [10][11]. Group 4: Clinical Implications - The findings indicate that significant weight gain is an independent risk factor for poor prognosis in obese patients with cardiovascular disease [11]. - Future research should focus on understanding the biological mechanisms behind weight fluctuation and its impact on mortality risk, particularly the pathways leading to increased death rates due to weight gain [11]. - Clinicians are urged to monitor weight changes in cardiovascular patients closely and provide timely interventions for those experiencing significant weight increases to improve long-term outcomes [11].

Core Viewpoint - The article emphasizes the growing global challenge of obesity and its significant health implications, highlighting the urgent need for effective weight management strategies in response to the "Healthy China 2030" initiative [5]. Global Overweight and Obesity Status - By 2030, over 2.9 billion adults worldwide are projected to have a high BMI, with 1.1 billion classified as obese (BMI ≥ 30 kg/m²), including 487 million men and 643 million women [7]. - In China, the proportion of adults with high BMI (BMI ≥ 25 kg/m²) has been steadily increasing, expected to reach 41% by 2025, with an obesity prevalence of 9%. The estimated number of adults with high BMI in China by 2030 is projected to be 515 million [7]. Non-Communicable Diseases and High BMI - In 2021, over 17 million people under 70 died from non-communicable diseases, with 11 million of these deaths attributable to avoidable risk factors, where high BMI accounted for 15% of these preventable early deaths [9]. - The report highlights four major categories of non-communicable diseases linked to high BMI: diabetes, cardiovascular diseases, cancer, and chronic respiratory diseases, with high BMI significantly increasing the risk of these conditions [9]. Effective Control of Overweight/Obesity - The World Health Organization stresses that regular physical activity is crucial for preventing and controlling obesity, as well as reducing the risk of various diseases, including hypertension, multiple cancers, osteoporosis, type 2 diabetes, stroke, and heart disease [10]. - Despite the benefits, approximately one-third of adults and 81% of adolescents globally do not meet recommended physical activity levels, with sedentary behavior becoming increasingly common due to lifestyle changes [10]. - Unhealthy dietary factors, such as high sodium intake, insufficient whole grain consumption, excessive processed meat and sugary drink intake, and inadequate fruit and vegetable consumption, are closely linked to the risk of non-communicable diseases and premature death [10].

Core Viewpoint - Novo Nordisk's semaglutide injection (brand name: Ozempic) has received approval from China's National Medical Products Administration (NMPA) for a new indication to treat chronic kidney disease (CKD) in adults with type 2 diabetes, marking it as the first and only GLP-1 receptor agonist approved for this purpose in China [2] Group 1: Clinical Trial Results - The FLOW clinical trial, a randomized, double-blind, placebo-controlled study, involved 3,533 patients with type 2 diabetes and CKD to evaluate the efficacy of 1.0 mg semaglutide in preventing kidney damage progression and reducing cardiovascular and kidney mortality risks [4] - Results indicated a significant 24% reduction in the risk of kidney disease progression and cardiovascular and kidney mortality for patients receiving 1.0 mg semaglutide compared to placebo, achieving the primary endpoint of the trial [5] Group 2: Meta-Analysis Findings - A meta-analysis published in The Lancet Diabetes & Endocrinology, involving 85,373 participants, demonstrated that GLP-1 receptor agonists, including semaglutide, reduced the risk of kidney failure by 16% and the risk of kidney function deterioration by 22% compared to placebo [6][7] - The overall risk of kidney failure, kidney function deterioration, and death due to kidney disease was reduced by 19% with the use of GLP-1 receptor agonists [7] Group 3: Broader Implications - The findings suggest that GLP-1 receptor agonists not only benefit patients with type 2 diabetes but also provide significant renal and cardiovascular protection for those with CKD, indicating a potential shift in clinical guidelines for managing these conditions [10] - The research emphasizes the need for further work to integrate these findings into clinical practice and improve access to GLP-1 receptor agonists for patients who could benefit from them [10]

Core Viewpoint - Semaglutide, a GLP-1 receptor agonist, effectively lowers blood sugar levels and has additional benefits in weight loss and cardiovascular risk reduction, making it a comprehensive treatment option for type 2 diabetes patients [2][4]. Mechanism of Action - Semaglutide mimics the natural GLP-1 hormone, promoting insulin secretion when blood sugar levels are high and suppressing glucagon release when blood sugar is normal, thus maintaining glucose balance [2][4]. - It reduces appetite through three main mechanisms: central nervous system effects, gastrointestinal effects, and changes in food preferences [5][9][11]. Central Nervous System Effects - Semaglutide acts on the hypothalamus, a key area for appetite regulation, activating GLP-1 receptors to reduce hunger and appetite [5][7]. Gastrointestinal Effects - It slows gastric emptying, increasing feelings of fullness and reducing food intake, which also helps in controlling postprandial blood sugar levels [9][11]. Changes in Food Preferences - Clinical studies indicate that semaglutide reduces the preference and intake of high-fat, fried, or sweet foods, likely due to its influence on the brain's appetite regulation centers [11]. Weight Loss Data - In the PIONEER PLUS study, participants taking 50mg and 25mg doses of oral semaglutide lost an average of 9.2kg (9.54%) and 7.0kg (7.26%) respectively over 68 weeks [14]. - The OASIS 1 study showed that participants in the 50mg group lost an average of 18.34kg (17.4%) [14]. - The OASIS 4 study reported a 13.6% (14.4kg) weight loss over 64 weeks, with potential for up to 16.6% (17.6kg) if all participants completed the treatment [15].

Core Viewpoint - The article emphasizes the urgent need for a national strategy to manage weight, highlighting the alarming obesity rates in China and the associated health and economic risks [4][10][16]. Group 1: National Strategy and Health Risks - The Chinese government has officially included "weight control" in its national strategy, launching a three-year "Weight Management Year" initiative to promote healthy lifestyles [4]. - The National Health Commission warns that if obesity is not curbed, the adult overweight and obesity rate in China could reach 70.5% by 2030, with children's rates potentially hitting 31.8% [4]. - Obesity is linked to ten major diseases, including cardiovascular diseases, diabetes, and various cancers, which pose significant public health challenges [7]. Group 2: Economic Impact - The World Health Organization predicts that obesity could lead to 8 million premature deaths in China over the next decade, resulting in a 0.8 percentage point decline in GDP growth [8]. - Research indicates that a 1-point decrease in the average BMI of a population can enhance the national competitiveness index by 0.3 points [9]. Group 3: Impact on Youth and Future Generations - The obesity rate among children and adolescents in China is nearing 30%, with projections suggesting that by 2030, nearly 50 million children will be overweight or obese [12]. - Obese children are at a higher risk for cardiovascular diseases, metabolic disorders, and psychological issues, which can persist into adulthood [13][14]. - The article highlights the potential long-term effects of obesity on military readiness and reproductive health, emphasizing the broader implications for national security and population growth [15]. Group 4: Societal Responsibility - The article stresses that weight management is not just a personal issue but a national concern, linking individual health to the future of the nation [16].

Core Viewpoint - The FDA has announced a new regulation that requires all imported products to undergo review, regardless of their value or size, following the cancellation of the small package exemption policy [2][3][4]. Group 1: Regulatory Changes - The previous exemption for products valued under $800 has been eliminated, meaning all products will now be subject to full review [3]. - This policy took effect on July 9 and aims to enhance the FDA's oversight of the U.S. supply chain and improve the identification of repeat violators [4]. - The new regulation applies to all product categories regulated by the FDA, including drugs, food, beverages, dietary supplements, cosmetics, medical devices, and biological samples [6]. Group 2: Impact on Imports - The FDA can now review all imported products declared through electronic systems, including those purchased online and transported across borders [5]. - Even small packages must adhere to the same regulatory standards as larger shipments, which may affect the circulation of weight-loss drugs in the "gray market" [8]. - A study indicated that in January, shipments of active ingredients from unregistered Chinese suppliers increased by 44% compared to the previous month [8]. Group 3: Implications of the Policy - The data does not account for packages that previously entered the U.S. under the exemption policy, suggesting that the actual import volume may be significantly higher than current statistics indicate [9]. - This policy adjustment is part of the FDA's efforts to close regulatory loopholes and strengthen comprehensive import reviews [10].

以下文章来源于内分泌早知道 ，作者关注内分泌的 内分泌早知道 . 深度分享内分泌用药经验、病例剖析、指南专业解读并紧跟国内外内分泌领域前沿进展。 现代社会的快节奏生活正在悄然重塑人类的睡眠模式，熬夜与紊乱的作息逐渐成为健康隐患。最新科学研究证实，睡眠问题不仅导致日 间疲惫，更会直接干扰血糖代谢稳态。来自JAMA Ne twor k Ope n的突破性研究《成人睡眠时长、入睡时间与连续血糖监测的变化轨 迹》首次采用动态监测方法，揭示睡眠时长缩短与入睡时间推迟会显著加剧血糖波动，这种影响甚至超过单纯熬夜的危害。该研究为理 解睡眠紊乱与代谢疾病之间的关联提供了全新证据。 这项开创性研究采用连续血糖监测技术，对受试者睡眠模式与血糖水平进行长期追踪。结果显示，持续睡眠不足6小时的人群，其血糖 波动幅度比睡眠充足者高出40%。更令人警惕的是，相比固定时间熬夜，不规律的就寝时间会导致更严重的血糖调节异常。研究团队指 出，人体生物钟与糖代谢存在精密协同，当入睡时间每日差异超过90分钟时，胰岛素敏感性会出现明显下降。这些发现完美解释了为何 轮班工作者和跨时区旅行者更容易出现代谢紊乱。 深入分析数据发现，睡眠对血糖的影响呈现双重 ...

Core Viewpoint - The emergence of GLP-1 receptor agonists provides a solution to the dual challenges of obesity and diabetes, breaking the vicious cycle between the two conditions [2][4]. Group 1: Understanding GLP-1 Receptor Agonists - GLP-1 is a crucial incretin hormone that regulates blood sugar levels by promoting insulin secretion, inhibiting glucagon release, and delaying gastric emptying, while also suppressing appetite [4]. - The first GLP-1 receptor agonist, exenatide, was developed from the saliva of the Gila monster, and subsequent drugs like liraglutide and semaglutide have been introduced with improved efficacy and dosing frequency [5][6]. Group 2: Efficacy of Liraglutide - Liraglutide has been shown to effectively control blood sugar levels and promote weight loss in both diabetic and non-diabetic obese patients, leading to its FDA approval for diabetes management in 2009 [6][9]. - Clinical trials demonstrated that participants using liraglutide lost significant weight compared to those on placebo, with reductions of up to 7.2 kg over 20 weeks [7][8]. Group 3: Semaglutide as a New Generation Drug - Semaglutide, introduced in 2017, allows for weekly injections and has shown to reduce body weight by an average of 15% in clinical trials, significantly outperforming previous weight loss medications [10][12]. - The STEP trials confirmed semaglutide's effectiveness in weight management, with participants achieving an average weight loss of 14.9% and improvements in body composition [12][14]. Group 4: Future Prospects - Oral formulations of semaglutide are being explored, showing promising results in managing blood sugar and weight, although currently limited to diabetes treatment [16][19]. - Ongoing studies continue to validate the safety and efficacy of semaglutide, with significant weight loss observed in various patient populations, indicating its potential as a leading treatment for obesity [20].

以下文章来源于内分泌早知道 ，作者关注内分泌的 内分泌早知道 . 深度分享内分泌用药经验、病例剖析、指南专业解读并紧跟国内外内分泌领域前沿进展。 你是否知道，就在此刻阅读这段文字时，你的身体可能正在自动进行着一种神奇的"运动"？最新科学研究表明，这个被大多数人视为无 意识小动作的「抖腿」行为，实际上可能是最轻松有效的燃脂方式。美国休斯敦大学在Ce ll旗下权威期刊iSc i e nc e发表的重磅研究证 实，当人们以特定方式（ 上下抖动而非左右摆动 ）进行抖腿时，能够显著 激活小腿比目鱼肌，使局部代谢水平提升2- 3倍 ，更令人惊 喜的是，这种看似简单的动作还能 全面改善身体的血糖和脂质代谢 ，其效果甚至超越了许多传统运动方式和间歇性禁食。 这项发现无疑为全球数以亿计的"抖腿族"正名。据统计，全球约三分之二的人口都有不同程度的抖腿习惯，尤其在久坐办公的现代人群 中更为普遍。以往被视为不雅的小动作，如今却被证明是藏在日常生活中的健康密码。研究人员特别指出，要达到最佳燃脂效果，需要 保持每天27 0分钟（即4.5小时）的抖腿时长。这个数字看似惊人，但考虑到现代人平均每天坐着的时间长达8- 10小时，只需在坐姿时 ...